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http://dx.doi.org/10.1016/j.kjms.201Abstract The purpose of this study was to compare the efficacy and safety of selective laser
trabeculoplasty (SLT) for patients with primary open-angle glaucoma (POAG) and pseudoexfo-
liative glaucoma (PXG). In this retrospective case series, 85 eyes (48 POAG, 37 PXG) of 85 pa-
tients were investigated. The medical records of patients who underwent SLT for POAG or PXG
were reviewed. The main outcome measures included intraocular pressure (IOP)-lowering ef-
fect and ocular side effects. The mean decrease in IOP differed significantly (p < 0.001) be-
tween eyes with POAG (4.4  2.1 mmHg) and eyes with PXG (6.1  3.6 mmHg) at
a mean follow-up period of 1 year. The rate of side effects, such as early IOP spike and uveitis,
did not significantly differ between the two groups. In conclusion, SLT has a greater IOP-
lowering effect in PXG compared with POAG.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Argon laser trabeculoplasty (ALT) was first described by
Wise and Witter in 1979 [1,2]. Since then, laser trabeculo-
plasty has undergone considerable development until itMahallesi, Akin Sokak, Akin Apart
il.com (N. Kara).
hsiung Medical University. Publish
3.01.005earned its current status as the most widely used laser
treatment for open-angle glaucoma (OAG). Several previous
studies have demonstrated ALT to be a safe and effective
procedure for reducing intraocular pressure (IOP) in pa-
tients with primary OAG (POAG) and various forms ofmani, Number 8/14, Bakırko¨y, Istanbul, Turkey.
ed by Elsevier Taiwan LLC. All rights reserved.
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However, results of histological studies have shown that
ALT causes coagulative damage, scarring on the trabecular
meshwork (TM), and membrane formation over the mesh-
work due to migrating endothelial cells. All of these side
effects are associated with the long-term deterioration of
the procedure’s effect. Moreover, these side effects limit
retreatment with ALT [3e5]. Over time, practitioners have
used many other types of lasers for laser trabeculoplasty,
such as krypton, diode, continuous wave, and frequency-
doubled Nd:YAG, in an attempt to avoid or at least lessen
these side effects.
Selective laser trabeculoplasty (SLT) is a relatively new
treatment modality for the treatment of OAG. It is a safe,
effective, and repeatable procedure that surgeons can use
as an adjunctive or primary treatment for patients whose
IOP is not adequately controlled with medical therapy [6].
SLT uses a Q-switched frequency-doubled Nd:YAG laser with
a 532-nm wavelength. The short duration of the SLT pulse
(3 ns) limits the laser’s destruction to the TM pigmented
cells, further preventing collateral tissue damage [7,8].
Several clinical studies have reported the effectiveness of
SLT in lowering IOP in patients with POAG and PXG [6,9e11].
The purpose of this study was to compare the efficacy and
safety of SLT treatment in cases of POAG and PXG.Methods
This study is a retrospective chart review of patients with
POAG and PXG who had undergone SLT at the Beyoglu Eye
Research and Training Hospital between May 2006 and Au-
gust 2010. The study was conducted in accordance with the
tenets of the Declaration of Helsinki. The study protocol
was reviewed and approved by the Local Institutional Ethics
Committee.
The study included patients who had a 12-month
follow-up after receiving SLT for POAG or PXG. Patients
were classified as having POAG if they had glaucoma and an
open, normal-appearing anterior chamber angle as well as
absence of other secondary causes of glaucoma. Patients
were classified as having PXG if they had glaucoma, an open
anterior chamber angle, and pseudoexfoliation.
Patients who had a history of uveitis, trauma, previous
laser or surgical therapy for glaucoma, and any ocular
condition precluding adequate visualization were excluded
from the present evaluation.
Demographic data including age, gender, glaucoma
diagnosis, and IOP-lowering medications were recorded.
Baseline examinations before SLT included best-corrected
visual acuity with a Snellen chart, a slit-lamp examination,
an IOP measurement with a Goldmann applanation ton-
ometer, a measurement of the central corneal thickness
using ultrasonic pachymetry, a measurement of thickness of
the retina nerve fiber layer (RNFL) using stratus optical
coherence tomography, and a dilated funduscopy. In addi-
tion, in each patient, the anterior chamber angle was
evaluated with a Goldmann goniolens, and the grade of TM
pigmentation was registered before treatment. Pigmenta-
tion on the anterior chamber angle was classified according
to the Scheie classification, based on the most posterior
structure visible in the angle.SLT procedure
All laser procedures were performed by two surgeons (N.K.
and C.A.). All of the patients were administered one drop of
topical proparacaine HCl 0.5% (Alcaine; Alcon, Fort Worth,
TX, USA) and a Latina SLT lens (Ocular Instruments, Belle-
vue, WA, USA) was used to visualize the angle. The laser
beam was focused on the pigmented TM. The initial energy
setting was 0.7 mJ, which was increased or decreased by
0.1 mJ until intermittent small cavitation bubbles were
visible. The inferior or nasal 180 was treated with con-
tiguous laser spots. One drop of brimonidine (0.2%) was
immediately administered after the laser treatment. Fluo-
rometholone (Flarex) eye drops were administered four
times a day for 1 week. The patients continued to receive
antiglaucomatous treatment identical to that given before
the laser therapy.
The patients were evaluated at 1 hour, 1 day, 1 month, 3
months, 6 months, and 1 year after the laser treatment. At
each visit, an ophthalmic examination was performed,
which included visual acuity measurement, slit-lamp bio-
microscopy, Goldmann applanation tonometry, and dilated
funduscopy. All IOP measurements were performed be-
tween 8:00 AM and 11:00 AM.
The main outcome measures were IOP changes, number
of antiglaucomatous medications, and postlaser complica-
tions such as IOP spikes, ocular discomfort, and intraocular
inflammation. Success was defined as IOP 21 mmHg
together with reduced topical medication usage and a 20%
reduction in IOP without additional medications, laser
treatments, or glaucoma surgeries. The IOP spike was
defined as an IOP rise of 5 mmHg than pretreatment IOP
on the postoperative 1st hour.
Statistical analysis
All statistical tests were performed using Statistical Pack-
age for the Social Sciences version 16. A Student t test and
Chi-square test were used to assess the differences be-
tween the groups. Prelaser and postlaser measurements
were compared using paired t test.
Results
The medical records of 91 eyes of 91 patients who under-
went SLT treatment for POAG and PXG were reviewed. Four
patients with less than 12-month follow-up and two pa-
tients who underwent ocular surgery during the follow-up
period were excluded. Therefore, the final analysis inclu-
ded 85 eyes of 85 patients. Forty-eight eyes of 48 patients
had been diagnosed with POAG, and 37 eyes of 37 patients
had been diagnosed with PXG. The characteristics of the
two groups of patients are shown in Table 1. There were no
statistically significant differences between the two groups
in terms of age, gender, preoperative IOP, number of
glaucoma medications, or baseline-measured cup-to-disc
ratio.
The mean baseline IOP (SD) was 22.7  2.1 mmHg in
the POAG group and 22.4  2.9 mmHg in the PXG group
(pZ 0.66). Table 2 presents the mean IOP values of the two
groups during the follow-up period. At all points in the
Table 1 Demographics and baseline characteristics of
patients.
POAG PXG p
Number of
eyes/patients 48/48 37/37 d
Gender
Female/male 30/18 25/12 p1: 0.65
Age
Mean  SD 63  10 66  8 p2: 0.15
Range 46e84 51e78
Baseline IOP (mmHg)
Mean  SD 22.7  2.1 22.4  2.9 p2: 0.66
Baseline number of medications
Mean  SD 1.9  1.0 2.1  1.1 p2: 0.23
Baseline c/d ratio
Mean  SD 0.61  0.16 0.66  0.14 p2: 0.16
Baseline RNFL thickness
Mean  SD 73.9  11.4 69.8  12.9 p2: 0.07
Angle pigmentation
Mean  SD 1.5  1.0 2.6  1.1 p2: 0.001
c/d ratio Z cup-to-disc ratio; IOP Z intraocular pressure;
p1 Z Chi-square test; p2 Z Independent student t test;
POAG Z primary open-angle glaucoma; PXG Z pseudoexfolia-
tive glaucoma; RNFL Z retina nerve fiber layer.
Table 3 Decrease in intraocular pressure values from
baseline to various time points.
POAG PXG pa
Baseline 22.7  2.1 22.4  2.9 0.66
1 wk 3.3  2.9 5.8  2.6 <0.001
1 mo 4.8  2.8 6.3  2.4 0.01
3 mo 4.3  2.6 6.3  2.1 <0.001
6 mo 4.5  1.9 5.8  3.1 0.01
1 y 4.4  2.1 6.1  3.6 0.002
POAG Z primary open-angle glaucoma; PXG Z pseudoexfolia-
tive glaucoma.
a Independent student t test.
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aser values for both the POAG and the PXG groups.
In addition, there was a statistically significant differ-
ence in mean IOP between the two groups at 1 week
(p < 0.001), 1 month (p Z 0.01), 3 months (p < 0.001), 6
months (p Z 0.01), and 1 year (p < 0.001) after SLT
treatment (Table 2).
At the 12-month follow up, IOP decreased by
4.4  2.1 mmHg in the POAG group and by 6.1  3.6 mmHg
in the PXG group. Table 3 shows the decrease in the IOP
values from baseline to follow-up. At 1 year, complete
success had been achieved in 54.2% of POAG eyes and 78.4%
of PXG eyes (p Z 0.039).Table 2 Mean intraocular pressure at baseline and at
various time points up to 1 year.
POAG pa PXG pb pc
Baseline 22.7  2.1 d 22.4  2.9 d 0.66
1 d 19.1  5.0 <0.001 18.3  4.2 <0.001 0.23
1 wk 19.3  2.6 <0.001 16.7  2.6 <0.001 <0.001
1 mo 17.9  2.7 <0.001 16.1  2.2 <0.001 0.002
3 mo 18.4  2.0 <0.001 16.2  2.4 <0.001 <0.001
6 mo 18.1  1.9 <0.001 16.7  2.3 <0.001 <0.001
1 y 18.2  1.7 <0.001 16.3  3.5 <0.001 <0.001
POAG Z primary open-angle glaucoma; PXG Z pseudoexfolia-
tive glaucoma.
a Paired t test for analyzing mean intraocular pressure (IOP)
values at baseline and during the follow-up period in POAG.
b Paired t test for analyzing mean IOP values at baseline and
during the follow-up period in PXG.
c Independent student t test for comparing IOP measurements
between the two groups.The mean number of antiglaucomatous drugs was
1.9  1.0 in the POAG group and 2.1  1.1 in the PXG group
at baseline and 2.4  1.30 and 2.0  1.02 at 12 months,
respectively. Although there were no significant differences
between the two groups at baseline (p Z 0.23), a signifi-
cant difference was found at 12 months (p Z 0.036). The
mean cup-to-disc ratio was 0.64  0.19 in the POAG group
and 0.67  0.16 in the PXG group at 12 months (p Z 0.21).
Adverse events following SLT were similar between the
two groups. An IOP spike greater than 5 mmHg was seen in
seven of the 48 eyes (14.5%) in the POAG group and in 10 of
the 37 eyes (27%) in the PXG group (p Z 0.17). Iritis was
observed in five of the 48 eyes (10.4%) in the POAG group
and in nine of the 37 eyes (24.3%) in the PXG group
(p Z 0.13). The rate of ocular discomfort was reported in
16 of the 48 eyes (33.3%) in the POAG group and in 10 of the
37 eyes (27%) in the PXG group (p Z 0.63). Sight-
threatening adverse events did not occur during the
follow-up period.Discussion
In this study, we compared the IOP-lowering efficacy and
safety of SLT in patients with POAG or PXG during 12 months
of follow-up. The clinical results have shown that SLT is
more effective in patients with PXG when compared with
the POAG group. However, there were no differences in
terms of adverse effects.
The first study demonstrating the efficacy of SLT was
reported by Latina et al. [6]. They found a mean 5.8-mmHg
IOP reduction after SLT treatment without any previous
laser trabeculoplasty [6]. Kim and Moon reported that
a 180 SLT resulted in a mean IOP reduction of 4.93 mmHg
(20.2%) from a baseline IOP value of 24.4 mmHg in 16 eyes
with POAG [12]. Damji et al. reported a 6.5-mmHg IOP
reduction after SLT treatment [13]. In our study, we ach-
ieved a mean 4.4-mmHg IOP reduction and a success rate of
54.2% in the POAG group. However, this success rate is
lower than the success rates of many previous studies
[6,12,13]. This lower success rate in POAG may be asso-
ciated with the amount of angle treated with SLT. Nagar
et al. reported that the 360 SLT treatment was more
effective than the 90 and 180 treatments, while Song
et al. demonstrated a high failure rate associated with the
180 SLT treatment [14,15].
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A poor response in a group of eyes with PXG after SLT
treatment was noted by Cellini et al. [16]. They determined
a transient success (IOP decrease rate 20%) rate for the
SLT treatment. After 1 month (average), the IOP level
returned to values similar to those observed at the base-
line. In another study, the reason for the poor response to
SLT treatment in eyes with PXG has been associated with
prevention of adequate laser-tissue interaction due to
pseudoexfoliative material [14]. By contrast, Melamed
et al. reported a 41% IOP reduction in five eyes with PXG,
and Shazly et al. reported a mean 5.3-mmHg IOP reduction
in patients with PXG [10,17].
This study is important in terms of comparing the results
of SLT treatment in POAG and PXG eyes in a greater number
of patients. Very few studies are available in the literature
regarding the comparison of clinical results of laser trabe-
culoplasty therapy for POAG and PXG. In 1996, Threlkeld
et al. compared the efficacy of ALT for the treatment of
POAG and PXG, and found that the initial response to ALT in
patients with PXG was greater; however, the long-term
outcome was similar for both groups [18]. Afterward,
Gracner has compared the IOP response of uncontrolled
PXG and POAG to the 180 SLT treatment in a prospective
clinical trial. He achieved an 18-month success rate of 64%
in the PXG group (nZ 10 eyes) and 78% success rate in the
POAG group (n Z 10 eyes), with no significant differences
between the two groups [19]. In a recent study, Shazly
et al. evaluated the safety and efficacy of SLT as a primary
therapy for the treatment of PXG (n Z 19 eyes) and POAG
(nZ 18 eyes). Their success rate was 74% for the PXG group
and 77% for the POAG group for up to 30 months of follow-
up [17]. In our study, we achieved a mean 6.1-mmHg IOP
reduction and a 78.4% success rate in the PXG group at 1
year after SLT treatment. The mean IOP reduction and
success rates were significantly greater in the PXG group
than in the POAG group.
Although still a controversial subject, the results of the
SLT treatment may be associated with a level of TM pig-
mentation because the laser energy is absorbed by melanin
granules in the trabeculum. An increased success rate has
been reported in the patients who had a higher percentage
of exfoliation or pigmentation [20]. Another study found
that increased angle pigment and degree of exfoliation
significantly correlate with a higher success rate at 7
months after SLT [20]. Anterior chamber angle pigmenta-
tion tends to be heavier in eyes with pseudoexfoliation. In
the current study, the degree of TM pigmentation was sig-
nificantly higher in eyes with PXG than in eyes with POAG,
which might be related to the higher success rate in the
PXG group.
The adverse effects of SLT are generally transient and
minor. Many published studies have reported a spike of IOP in
somepatients, but all of these cases resolvedquickly through
observation or by administering additional antiglaucomatous
medications. The reported rate of IOP spikes (5 mmHg)
within 1 day following 180 SLT treatment varies among
studies, ranging from 10% to 16% in patients with POAG or
ocular hypertension [14,21,22]. Shazly et al. reported that an
IOP spike was seen in 28% of eyes with PXG and in 21% of eyes
with POAG [17]. In our study, the rate of IOP spikewas slightly
higher in thePXGgroup (27%) than in thePOAGgroup (14.5%).The post-SLT IOP elevations have been associated with the
level of angle pigmentation [23,24]. The higher rate of IOP
spike after SLT is not surprising in our patients with PXG due
to the higher percentage of TM pigmentation in eyes with
PXG. Therefore, SLT should be carefully performed on any
patient with PXG and lower energy settings are recom-
mended for these eyes [23]. In addition, the rate of other
adverse effects such as transient ocular discomfort and
inflammation was not significantly different between the
POAG group and the PXG group.
This study was limited by its retrospective study design.
Although the severity of glaucoma based on a visual field test
has not been considered as an inclusion criterion for either
group, the number of pre-SLT glaucoma medications, the
baseline cup-to-disc ratio, baselineRNFL thicknesses,and IOP
values were not significantly different between the groups.
Moreover,we treated the180 of theTM.Perhaps the360 SLT
treatment would have demonstrated different results.
In conclusion, SLT is an effective and well-tolerated ther-
apy for patientswith POAGand PXG. In addition, SLTseems to
be more effective in patients with PXG than in patients with
POAG as adjunctive therapy. These findings support the con-
sideration of SLT as a preferred treatment for PXG.References
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